J
Jeffrey J. Rade
Researcher at University of Massachusetts Medical School
Publications - 70
Citations - 6497
Jeffrey J. Rade is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Thromboxane & Platelet. The author has an hindex of 24, co-authored 68 publications receiving 5733 citations. Previous affiliations of Jeffrey J. Rade include Johns Hopkins University School of Medicine & University of Massachusetts Amherst.
Papers
More filters
Journal ArticleDOI
Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk.
M. T. Olson,Thomas S. Kickler,John A. Lawson,Rhondalyn C. McLean,Jayesh Jani,Garret A. FitzGerald,Jeffrey J. Rade,Jeffrey J. Rade +7 more
TL;DR: Compared to the first‐generation ELISA, 11‐dehydro TXB2 measured by the monoclonal antibody‐based ELISA failed to associate with the risk of vein graft occlusion and was confounded by interference from 11‐ dehydro‐2,3‐dinor TXB 2 which reduced the accuracy and clinical utility of this second‐generation assay.
Journal ArticleDOI
Thromboxane A2 Generation, in the Absence of Platelet COX-1 Activity, in Patients With and Without Atherothrombotic Myocardial Infarction
Andrew P. DeFilippis,Oluwasegun S. Oloyede,Efstathia Andrikopoulou,Amy K. Saenger,Joel M Palachuvattil,Yetunde A. Fasoro,Eliseo Guallar,Roger S. Blumenthal,Thomas S. Kickler,Allan S. Jaffe,Gary Gerstenblith,Steven P. Schulman,Jeffrey J. Rade +12 more
TL;DR: Differences in TxA2 production, in the absence of platelet COX-1 activity, between those with and without atherothrombotic myocardial infarction are highlighted and suggest that 11-dehydro-2,3-dinor-TxB2 may be critical to the biology of atherostrombosis.
Journal ArticleDOI
Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization
Tyler J Gluckman,Jodi B Segal,Natalie L. Fredde,Kenneth E. Saland,Jayesh Jani,Jeanine M. Walenga,Margaret Prechel,Kathleen M. Citro,David A. Zidar,Emily Fox,Steven P. Schulman,Thomas S. Kickler,Jeffrey J. Rade +12 more
TL;DR: Serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention and relationships were made across antibody induction, heparin exposure, and clinical outcome at 6 months.
Journal ArticleDOI
Retroviral vector-mediated expression of hirudin by human vascular endothelial cells: implications for the design of retroviral vectors expressing biologically active proteins.
TL;DR: High level retrovirus-mediated secretion of biologically active hirudin from endothelial cells in vitro is achieved and use of these vectors may permit sustained local antagonism of thrombin activity in vivo.
Journal ArticleDOI
PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study.
Athan Kuliopulos,Paul A. Gurbel,Jeffrey J. Rade,Carey Kimmelstiel,Susan E. Turner,Kevin P. Bliden,Elizabeth K. Fletcher,Daniel H. Cox,Lidija Covic +8 more
TL;DR: In this first-in-patient experience, PZ-128 added to standard antiplatelet therapy appeared to be safe, well tolerated, and potentially reduced periprocedural myonecrosis, thus providing the basis for further clinical trials.